Tuesday 26 September

07.30-09.00             EDUCATIONAL TRACK SESSION 3 : ABOVE AND BELOW THE DIAPHRAGM

CHAIRS: Arne Neyrinck,Leuven, Belgium
              Annemarie Weissenbacher, Oxford, United Kingdom

07:30                     Learning objectives Assessment

07.45                      Old and new listing criteria for lung and heart transplantation
                               John Dark, Newcastle, United Kingdom

08.00                      Old and new listing criteria for liver, pancreas and intestinal transplantation
                               Peter Friend, Oxford, United Kingdom

08.15                      How do factors from above the diaphragm impact on the outcome of transplantation of organs below the diaphragm?
                               Stephan Eschertzhuber, Innsbruck, Austria

08.30                      Combined transplanted patients - Which organ drives the immunosuppressive regimen? 
                               Nassim Kamar, Toulouse, France

08.45                      Learning outcomes assesment

 

07.30-09.00             EDUCATIONAL TRACK SESSION 4 : PATHOPHYSIOLOGY AND ENDPOINTS ON TOLERANCE 

CHAIRS: Christine S. Falk, Hannover, Germany
              Nina Pilat, Vienna, Austria

07:30                     Learning objectives Assessment

07.45                      Clinical tolerance studies
                               Megan Sykes, New York, United States

08.00                      Endpoints and biomarkers for clinical tolerance
                               Birgit Sawitzki, Berlin, Germany

08.15                      Macrophages and the induction of tolerance
                               Jordi Orchando, New York, United States

08.30                      T-reg induced allograft tolerance in human
                               Giovanna Lombardi, London, United Kingdom

08.45                      Learning outcomes assesment

 

08.00-09.00             Full oral sessions

                                Brief oral sessions

 

09:10 - 10:40           STATE OF THE ART 4 | NEW CONCEPTS IN TRANSPLANT INFECTIOUS DISEASES: MICROBIOTA, AND BEYOND

New tools have allowed an unprecedented genetic insight into the composition of our microbiota and our virome. First, we explore the role of the virome and microbiota as it relates to transplantation including potential clinical applications. We aim to elaborate on the impact in transplantation on an individual and epidemiological level. The immunomodulatory role of viruses in transplantation are often mentioned – but does this concept hold up? A critical appraisal of the concept of the indirect effects of viruses is presented. The new anti-HCV drugs have made eradication of HCV in virtually all patients a realistic goal, but how important is a complete control of viral replication in the context of HCV and other viruses?

CREATED BY: Marina Berenguer, Valencia, Spain
                       Nicolas Müller, Zurich, Switzerland

CHAIRS: Maria Luisa Alegre, Chicago, United States
              Marina Berenguer, Valencia, Spain

09.10                      The virome and microbiome in health and disease
                               Wang Dave, St. Louis, United States

09.30                      Knowledge and clinical applications of microbiota in transplantation
                               Frederick Bushman, Philadelphia, United States

09.50                      Viruses and the recipient immune response: relevant crosstalk in transplantation
                               Oriol Manuel, Lausanne, Switzerland

10.10                      The impact of HCV treatment on liver transplantation
                              Audrey Coilly, Paris, France

 

09:10 - 10:40           STATE OF THE ART 5 | CELL THERAPY IN CLINICAL TRIALS

Cell therapy may be a suitable adjunct to conventional immunosuppression. Despite a major enthusiasm, however, major issues emerged in the first clinical applications. The question now is: how can technical and regulatory hurdles be overcome within a reasonable time frame? Will cell therapy ever be commercially interesting and will its implementation enhance solid organ transplantation? Experts share their experience and explain what we might expect from cell therapy tomorrow and in 10 years.

CREATED BY: Pietro Cippà, Zurich, Switzerland
                       Marc Dahlke, Regensburg, Germany

CHAIRS: Marc Dahlke, Regensburg, Germany
              Thomas Wekerle, Vienna, Austria

09.10                      Technical and regulatory issues. From the idea to the clinical application
                               Marlies Reinders, Leiden, The Netherlands

09.30                      Sharing clinical experience. What can we learn from hematologists?
                               Francesco Dazzi, London, United Kingdom

09.50                      Translational studies. Why do we need cell therapy if we cannot avoid severe immunosuppression?
                               Suzanne T. Ilstad, Louisville, United States

10.10                      The future: Clinical applications of stem cells in the context of transplantation vs. regeneration?    
                               Martin J. Hoogduijn, Rotterdam, The Netherlands

 

09:10 - 10:40           STATE OF THE ART 6 | ONE FOR ALL OR ALL FOR ONE; MOVING AWAY FROM PROTOCOLIZED MEDICINE

The ultimate goal of transplantation is long-term survival with a well-functioning graft. Operationalization of post-transplant care with protocols based on evidence from clinical trials has had an important impact on the overall outcome in transplantation. It is increasingly recognized though, that the ‘one size fits all’ approach does not always optimally reflect the patient’s individual need. Hence, the concept of personalized medicine is on everyone’s lips. This session aims to confront the reality by focusing on four important topics in the field.

CREATED BY: Georg Böhmig, Vienna, Austria
                       Nicolas Müller, Zurich, Switzerland

CHAIRS: Georg Böhmig, Vienna, Austria
              Nicolas Müller, Zurich, Switzerland

09.10                      Is transplantation ready for systems medicine?            
                               Rainer Oberbauer, Vienna, Austria

09.30                      Individualized antimicrobial prophylaxis
                               Jay Alan Fishman, Boston, United States

09.50                      Phenotypic diversity of rejection and allograft dysfunction
                               Phil Halloran, Edmonton, Canada

10.10                      Tailored immunosuppression
                               Christian Hugo, Dresden, Germany

 

11.10-12.40          ASIA LEADING THE WAY (Joint Session with the Asian Society for Transplantation)

This session was jointly organized with the Asian Society for Transplantation and aims to highlight some of the significant advancements in transplantation achieved in the recent past. We are proud to bring to your attention, programs and topics with significant thrive from our partners in Asia.  

CHAIRS: Jan Lerut, Brussels, Belgium
              Dennis Serrano, Quezon City, Philippines

11.20                      Tissue Repair and its Relevance to Transplantation
                               Nathaniel S. Hwang, Seoul, Korea

11.40                      Challenges in Increasing Organ Donation in Asia
                               Romina Danguilan, Manila, Philippines

12.00                      ABO Incompatible Kidney Transplantation: Future Directions
                               Shiro Takahara, Osaka, Japan

12.20                      State of the Art of Living Donor Liver Transplantation 
                               Chao Long Chen, Kaohsiung City, Taiwan

 

11.10-12.40             BIG BANG 3 | INNOVATION IN IMMUNOMEDICATION: THE MODERN PROMETHEUS

Putting their feet in those of Dr Frankenstein, scientists have started stitching disparate biological pieces to create new therapeutic opportunities. far from sci-fi fantasies, these therapeutic innovations have already shown promising results in the field of cancer therapy. Their potential to revolutionize solid organ transplantation will be scrutinized during this Big Bang session.

CREATED BY: Josep Maria Grinyó, Barcelona, Spain
                       Olivier Thaunat, Lyon, France

CHAIRS: Adrian Morelli, Pittsburg, United States
             Josep Maria Grinyó, Barcelona, Spain

11.10                      Deciphering and targeting protein-protein interactions: a new challenge in biomedicine
                               Juan Fernández Recio, Barcelona, Spain

11.30                      The potential of bispecific antibodies
                              Jeffrey S. Miller, Minneapolis, United States

11.50                      Alloantigen-specific regulatory T-cells generated with a chimeric antigen receptor
                               Megan Levings, Vancouver, Canada

12.10                      Systems biology applications for prognostication and therapeutics
                               Patrick Aloy, Barcelona, Spain

 

11.10-12.40              Full oral sessions

                               Elevator Pitch sessions

 

13.00-14.00             Corporate Parallel lunch Symposia

                               Brief oral sessions

 

13.00-14.00          SURROGATE ENDPOINTS INTERNATIONAL WORKSHOP

Drug development in transplantation has diminished due to the lack of fitting endpoints, the long timespan between transplantation and graft failure and the low rates of early rejection. At the same time, we find patients suffering from long-term graft loss. Hence it is paramount to establish new principles to allow development of novel therapeutics to treat and prevent this from happening. One of the main objectives in our thrive to address this is to identify and validate surrogate markers for long-term graft outcome and identify novel endpoints for trials and drug development. The field of transplantation is facing one of the greatest challenges hindering further advancement of this field and all individuals and institutions involved in this field need to work together to prevail.
In this interactive session, we will discuss the need for new endpoints in the field of transplantation, the potential and problems with histology, the applicability of donor-specific antibodies, and the promise of combined calculated markers as surrogate endpoints. We will discuss the progress that has and can be achieved by transplant societies and health authorities. The session will focus on kidney transplantation, although the methodology and conclusions are likely valid also for other organs.

CREATED BY: Maarten Naesens, Leuven, Belgium
                       Stefan Schneeberger, Innsbruck, Austria

CHAIRS: Maarten Naesens, Leuven, Belgium
              Stefan Schneeberger, Innsbruck, Austria

13.00                      Why do we need new endpoints
                               Mark Stegall, Rochester, United States

13.10                      The potential of combined calculated surrogate endpoints
                               Alexandre Loupy, Paris, France

13.22                      The difficult but important place of histology as endpoint
                               Maarten Naesens, Leuven, Belgium

13.34                      DSAs as surrogate endpoint for drug development
                               Peter Nickerson, Winnipeg, Canada

13.46                      Panel discussion

 

14:05-15:35             PLENARY SESSION  3 | INNOVATION UNDER PRESSURE: TRANSPLANT PATIENT CARE IN 2020

Health care is undergoing a fundamental change. While new fields in medicine are emerging and short-term results are satisfactory, long-term care of patients after transplantation is more complex and challenging than ever. While novel technologies may help to effectively monitor patients after transplantation, novel structures and business models are warranted to ensure optimal patient care and advancement of the field.

CREATED BY: Marina Berenguer, Valencia, Spain
                       Antonio Roman, Barcelona, Spain

CHAIRS: John Forsythe, Edinburgh, United Kingdom
              Christophe Legendre, Paris, France

14.05                      Prospects and pushbacks in hand face uterus abdominal wall penile transplant and others
                               Wei-Ping Andrew Lee, Baltimore, United States

14.25                      Beyond survival: quality of life after transplantation
                               Lianne Singer, Toronto, Canada

14.45                      New tech for new patients: digital communication and self-monitoring  
                               Giral Magali, Nantes, France

15.05                      New models for patient care: wish for what you care for
                               Marcel Levi, London, United Kingdom

 

16.00 - 17.00             BIG BANG 4 | AGEING AND IMMORTALITY

In this session, we discuss the changing demographics of donors and recipients and its impact on transplantation in reference to organ quality, ischemia-reperfusion injury and immunosenescence. In addition, the biology of ageing and the concept of accelerated ageing after transplantation with its implications on the fate of the graft and the patient are being addressed. As a consequence of the changing demographics, transplant allocation organisations are implementing age-matching in their allocation procedures. The benefits and the potential drawbacks of these important changes are discussed. Finally, we will evaluate innovative ways to halt or slow down these ageing processes, and discover the clues to immortality.

CREATED BY: Maarten Naesens, Leuven, Belgium
                       Olivier Thaunat, Lyon, France

CHAIRS: Maarten Naesens, Leuven, Belgium
              Olivier Thaunat, Lyon, France

16.00                      Older graft, older recipients, young ideas
                              Stefan Tullius, Boston, United States

16.20                      Accelerated ageing after transplantation
                              Peter Stenvinkel, Stockholm, Sweden

16.40                      Halting aging: the science of rejuvenation
                              Brian Kennedy, Novato, United States

 

16.00-17.00             Brief oral sessions

 

16.00-17.00          THE DEVIL'S ADVOCATE: CONTRADICTORY DISCUSSION OF CLINICAL SCIENCE

The format of this session will be the presentation of the article by the author followed by a critical discussion by the “opponent” and a rebuttal and general discussion with the audience. It will be a highly interactive session.

CREATED BY: Rainer Oberbauer, Vienna, Austria
                       Josep Maria Grinyó, Barcelona, Spain

CHAIRS: Rainer Oberbauer, Vienna, Austria
              Josep Maria Grinyó, Barcelona, Spain

Case1. Ethical debate
Allocating Organs to Cognitively Impaired Patients.
Scott D. Halpern, M.D., Ph.D., and David Goldberg, M.D., M.S.C.E. N Engl J Med 2017; 376:299-301January 26, 2017DOI: 10.1056/NEJMp1613858

16:00                     Defender: Scott Halpern, United States
16:10                     Opponent: Michael Bos, Leiden, The Netherlands
16:20                     Discussion

Case 2. Expensive but useless?
Clinical value of C1q assay in antibody-mediated rejection
Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. Wiebe, Gareau, Pochinco, Gibson, Ho, Birk, Blydt-Hansen, Karpinski, Goldberg, Storsley, Rush, Nickerson. Am J Transplant. 2017 Mar;17(3):703-711. doi: 10.1111/ajt.14015. Epub 2016 Oct 3.

16:30                     Defender: Peter Nickerson, Winnipeg, Canada
16:40                     Opponent: Denis Glotz, Paris, France
16:50                     Discussion

17.00-18.30            Corporate Plenary/Parallel Symposium

                              Full oral sessions

 

17.05-18.35           ESOT General Assembly

18.30-19.30           Elevator Pitch sessions

                              Brief oral sessions